Trial Profile
Antibody-Mediated Rejection Associated With Higher Serum Levels of CXCL13 and CCL21 in Renal Transplant Patients and Altered By Bortezomib/Rituximab Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record